- Condition: Multi-vessel Diseases, Angina
Interventions: Device: Sirolimus-eluting stent (Cypher SelectTM, Cordis, Miami, FL); Device: Everolimus-eluting stent(Xience Prime®, Abbott Vascular, Santa Claea, CA); Drug: Pravastatin 20mg; Drug: Atorvastatin 40mg
Sponsors: Yonsei University; Yonsei University
Recruiting - verified May 2013 - Condition: Diabetes
Interventions: Other: Experimental Study Product; Other: Control Study Product
Sponsors: Abbott Nutrition; Abbott Nutrition
Not yet recruiting - verified May 2013 - Condition: Diabetes
Interventions: Other: Experimental Study Product; Other: Control Study Product
Sponsors: Abbott Nutrition; Abbott Nutrition
Not yet recruiting - verified May 2013 - Conditions: Coronary Artery Disease; Myocardial Ischemia
Interventions: Device: XIENCE PRIME®; Device: Absorb™ BVS
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified May 2013 - Condition: Hip Fractures
Interventions: Dietary Supplement: Supplement with HMB and vitamin D; Dietary Supplement: Standard nutritional supplement
Sponsors: Hospital Clinic of Barcelona; Hospital Clinic of Barcelona; Abbott
Not yet recruiting - verified May 2013 - Condition: Female Infertility
Interventions: Drug: Dydrogesterone 30 mg; Drug: Micronized Progesterone 600 mg; Drug: Placebo progesterone; Drug: Placebo dydrogesterone
Sponsors: Abbott; Abbott; Quintiles
Not yet recruiting - verified May 2013 - Conditions: Acute Coronary Syndrome; Myocardial Infarction
Intervention: Device: High-sensitivity troponin I assay
Sponsors: University of Edinburgh; University of Edinburgh; NHS Lothian; NHS Greater Glasgow and Clyde; Abbott Diagnostics Division
Not yet recruiting - verified May 2013 - Conditions: Vascular Death; Myocardial Infarction; Stroke; Cardiac Surgery
Intervention:
Sponsors: Population Health Research Institute; Population Health Research Institute; Abbott Diagnostics Division
Not yet recruiting - verified April 2013 - Condition: Atrial Fibrillation
Interventions: Device: nMARQ Navigation Catheters; Device: NaviStar ThermoCool Catheters
Sponsors: Biosense Webster, Inc.; Biosense Webster, Inc.
Recruiting - verified April 2013 - Condition: Cocaine Addiction
Interventions: Drug: Propranolol; Drug: Placebo
Sponsors: Medical University of South Carolina; Medical University of South Carolina
Not yet recruiting - verified April 2013 - Condition: Growth and Tolerance
Interventions: Other: Control Formula; Other: Experimental Formula 1; Other: Experimental Formula 2; Other: Human Milk
Sponsors: Abbott Nutrition; Abbott Nutrition
Not yet recruiting - verified March 2013 - Condition: Anxiety
Intervention: Other: Lavender aromatherapy inhalers
Sponsors: Allina Health System; Allina Health System
Not yet recruiting - verified March 2013 - Conditions: Diabetes Mellitus; Hyperglycemia
Intervention: Device: Closed-loop blood glucose control
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Boston University
Recruiting - verified March 2013 - Condition: Gastro-Intestinal Tolerance
Intervention: Other: Study Oral Nutritional Supplement
Sponsors: Abbott Nutrition; Abbott Nutrition
Not yet recruiting - verified February 2013 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: AbbVie; Abbott (Egypt)
Recruiting - verified May 2013 - Condition: HIV
Intervention: Genetic: Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF‐T), given via intravenous infusion.
Sponsors: University of Pennsylvania; University of Pennsylvania
Recruiting - verified December 2012 - Condition: Pre-term Infants
Intervention: Other: study pre-term formula
Sponsors: Abbott Nutrition; Abbott Nutrition
Recruiting - verified January 2013 - Condition: Cardiovascular Diseases
Intervention: Device: MitraClip
Sponsors: Evalve; Evalve
Not yet recruiting - verified January 2013 - Conditions: Rheumatoid Arthritis; Ankylosing Spondylitis; Psoriatic Arthritis
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); Raffeiner GmbH; BIOCONSULT GmbH
Recruiting - verified April 2013 - Condition: Vertigo
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified February 2013 - Conditions: Chronic Kidney Disease Stage V; Hemodialysis
Intervention:
Sponsors: AbbVie; Abbott (Venezuela)
Recruiting - verified February 2013 - Condition: Idiopathic Scoliosis
Interventions: Procedure: Hypercorrective night-time brace; Behavioral: Scoliosis specific exercises.; Other: Self-mediated physical activity.
Sponsors: Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Stockholm County Council, Sweden; The Swedish Research Council
Recruiting - verified January 2013 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Condition: Ankylosing Spondylitis
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Conditions: Chronic Total Occlusion of Coronary Artery; Coronary Occlusion; Coronary Artery Disease; Coronary Artery Restenosis; Coronary Artery Stenosis; Coronary Disease; Coronary Restenosis
Intervention: Device: Absorb Bioresorbable Vascular Scaffold
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified February 2013 - Conditions: Coronary Artery Disease; Coronary Artery Stenosis; Coronary Disease; Coronary Stenosis
Interventions: Device: Absorb BVS; Device: XIENCE V or XIENCE PRIME
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified April 2013 - Condition: Patients Suspected to Have Difficult Intubation
Intervention:
Sponsors: AbbVie; Abbott (Egypt)
Recruiting - verified March 2013 - Condition: Parkinson's Disease
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Condition: Lactation
Interventions: Dietary Supplement: Similac Prenatal Vitamin soft-gel capsule; Dietary Supplement: Placebo (soybean oil and dl-alpha-tocopheryl acetate)
Sponsors: Abbott Nutrition; Abbott Nutrition
Recruiting - verified December 2012 - Condition: Rheumatoid Arthritis
Intervention: Biological: adalimumab
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified March 2013 - Condition: Patient Reported Outcomes
Intervention:
Sponsors: Duke University; Duke University; The Bravewell Collaborative
Not yet recruiting - verified April 2013 - Condition: Parkinson's Disease
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified May 2013 - Conditions: Pulmonary Hypertension; COPD
Intervention: Drug: Inhaled Treprostinil Therapy
Sponsors: University of Colorado, Denver; University of Colorado, Denver
Not yet recruiting - verified December 2012 - Condition: Angioplasty, Balloon, Coronary
Intervention: Procedure: percutaneous coronary intervention using drug eluting stent
Sponsors: Chonbuk National University Hospital; Chonbuk National University Hospital
Recruiting - verified December 2012 - Condition: Infection
Intervention:
Sponsors: Abbott Diagnostics Division; Abbott Diagnostics Division
Recruiting - verified April 2013 - Condition: Chronic Hepatitis C Infection
Interventions: Drug: ABT-450/r/ABT-267; Drug: ABT-333; Drug: Ribavirin; Drug: Placebo for ribavirin
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified January 2013 - Condition: Coronary Artery Disease
Intervention:
Sponsors: AUM Cardiovascular, Inc.; AUM Cardiovascular, Inc.
Recruiting - verified April 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: ABT-494; Drug: Placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified March 2013 - Condition: Major Depressive Disorder
Interventions: Drug: ABT-436; Drug: Escitalopram; Drug: Placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Condition: Hepatitis C
Interventions: Drug: ABT-450/ritonavir; Drug: ABT-333; Drug: ABT-267
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Not yet recruiting - verified January 2013 - Condition: Advanced Parkinson's Disease
Intervention: Drug: Levodopa-Carbidopa Intestinal Gel
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified March 2013 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified May 2013 - Conditions: Heart Failure; Dementia; Cancer
Intervention: Other: Care team
Sponsors: Allina Health System; Allina Health System
Recruiting - verified December 2012 - Condition: Healthy Subjects
Interventions: Other: Study product containing 6 mg lutein in high-oleic safflower oil; Other: Study product containing 6 mg lutein in mono-diglyceride oil
Sponsors: Abbott Nutrition; Abbott Nutrition
Recruiting - verified November 2012 - Condition: Revised Medication Guide Formats
Intervention:
Sponsors: Northwestern University; Northwestern University; University of Illinois; Abbott
Not yet recruiting - verified November 2012 - Condition: Acute Myocardial Infarction
Interventions: Device: STENTYS self-apposing stent; Device: VISION balloon-expandable stent
Sponsors: Stentys; Stentys
Not yet recruiting - verified November 2012 - Conditions: SpA; PsA
Intervention: Behavioral: Education and Feedback
Sponsors: Pope Research Corporation; Pope Research Corporation; AMOSO; CIORA; Abbott
Recruiting - verified February 2013 - Condition: Cataract
Interventions: Device: Tecnis Multifocal Intraocular Lens; Device: Monofocal Intraocular Lens
Sponsors: Abbott Medical Optics; Abbott Medical Optics
Recruiting - verified April 2013 - Conditions: Psoriasis; Vascular Inflammation; Coronary Atherosclerosis
Interventions: Biological: Adalimumab; Other: Placebo
Sponsors: Innovaderm Research Inc.; Innovaderm Research Inc.; Abbott; Montreal Heart Institute
Recruiting - verified May 2013 - Condition: Chronic Hepatitis C Infection
Interventions: Drug: ABT-450/r/ABT-267; Drug: ABT-333; Drug: ribavirin (RBV)
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Condition: ST Segment Elevation Myocardial Infarction
Intervention:
Sponsors: Peking University First Hospital; Peking University First Hospital; Abbott Vascular; Sanofi
Recruiting - verified October 2012 - Condition: Chronic Hepatitis C Infection
Interventions: Drug: ABT/450/r/ABT-267; Drug: ABT-333; Drug: Ribavirin (RBV); Drug: Placebo for ABT-450/r/ABT-267; Drug: Placebo for ABT- 333; Drug: Placebo for Ribavirin (RBV)
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Condition: Type 2 Diabetes Mellitus
Interventions: Other: MNT according to AND EBNPG for Type 2 DM; Other: Usual Nutrition Care
Sponsors: Academy of Nutrition and Dietetics; Academy of Nutrition and Dietetics; Indian Institute of Nutritional Sciences; Academy of Nutrition and Dietetics Foundation; Abbott Healthcare Private Limited (in India)
Recruiting - verified February 2013 - Conditions: HIV; Hypercholesterolemia; Dyslipidemia
Intervention:
Sponsors: Helios Salud; Helios Salud; Abbott
Recruiting - verified October 2012 - Condition: Psoriasis
Intervention: Drug: Humira Then Humira plus 3 B vitamins
Sponsors: Wayne State University; Wayne State University; Abbott
Recruiting - verified October 2012 - Conditions: Angina; Chronic Coronary Occlusion; Coronary Artery Disease; Coronary Artery Stenosis; Myocardial Ischemia
Interventions: Device: Subjects receiving XIENCE Prime - Long Length (LL); Device: Subjects receiving XIENCE Prime - Core Length
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified November 2012 - Condition: Alzheimer's Disease
Intervention: Drug: ABT-126
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Condition: Ovarian Cancer
Interventions: Drug: Veliparib; Drug: Topotecan
Sponsors: Vejle Hospital; Vejle Hospital; Abbott
Recruiting - verified April 2013 - Conditions: Childhood Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma
Interventions: Drug: tivantinib; Drug: erlotinib hydrochloride; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified February 2013 - Condition: Systemic Lupus Erythematosus
Interventions: Drug: ABT-199; Other: Placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified March 2013 - Condition: Hepatitis C Virus
Interventions: Drug: ABT-450/r; Drug: ABT-267; Drug: Ribavirin
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Condition: Anesthesia, General
Intervention:
Sponsors: AbbVie; Abbott (China)
Recruiting - verified March 2013 - Condition: Astigmatism
Intervention: Device: LASIK
Sponsors: Abbott Medical Optics; Abbott Medical Optics
Recruiting - verified January 2013 - Condition: Hyperopia
Intervention: Device: LASIK correction of hyperopic refractive errors
Sponsors: Abbott Medical Optics; Abbott Medical Optics
Recruiting - verified January 2013 - Condition: Schizophrenia
Interventions: Drug: ABT-126; Drug: ABT-126; Drug: Placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified March 2013 - Condition: Irregular Menstrual Cycle
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified February 2013 - Condition: Alzheimer's Disease
Intervention: Drug: ABT-126
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Condition: Crohn's Disease
Interventions: Drug: Adalimumab; Drug: Adalimumab; Drug: Placebo
Sponsors: University of Michigan; Peter Higgins; Abbott
Not yet recruiting - verified August 2012 - Condition: Infants
Intervention:
Sponsors: Abbott Nutrition; Abbott Nutrition
Recruiting - verified August 2012 - Condition: Myopia
Intervention: Device: LASIK correction of myopic refractive errors
Sponsors: Abbott Medical Optics; Abbott Medical Optics
Recruiting - verified February 2013 - Conditions: Coronary Heart Disease; Heart Failure; HIV; AIDS; Metabolic Syndrome
Intervention: Other: Comprehensive non invasive cardiovascular examination
Sponsors: University Hospital, Essen; University Hospital, Essen; HIV-HEART Study Investigative Group; German Heart Failure Network; German Federal Ministry of Education and Research; Bristol-Myers Squibb GmbH & Co. KG; ViiV Healthcare; Gilead Sciences GmbH; Janssen-Cilag GmbH; Abbott; Boehringer Ingelheim Pharma GmbH & Co. KG; MSD Sharp & Dohmen GmbH
Recruiting - verified April 2012 - Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Interventions: Drug: pegylated liposomal doxorubicin (PLD); Drug: VTX-2337; Drug: Placebo
Sponsors: VentiRx Pharmaceuticals Inc.; VentiRx Pharmaceuticals Inc.; Gynecologic Oncology Group
Recruiting - verified April 2013 - Condition: Type 1 Diabetes
Interventions: Device: FlorenceD or similar closed loop glucose control system; Device: CSII with real-time CGM
Sponsors: University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Profil Institut für Stoffwechselforschung GmbH; Medical University of Graz
Recruiting - verified January 2013 - Condition: Bacteriuria
Interventions: Dietary Supplement: 2 cranberry capsules; Dietary Supplement: Placebo
Sponsors: Yale University; Yale University
Recruiting - verified May 2013 - Condition: Human Immunodeficiency Virus Infection
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified May 2013 - Condition: Coronary Artery Disease
Intervention: Device: Everolimus eluting stents
Sponsors: Northern Hospital, Australia; Northern Hospital, Australia; Abbott Vascular
Recruiting - verified January 2013 - Conditions: HIV; Tuberculosis
Intervention: Drug: Rifabutin
Sponsors: Medical Research Council; Justine Boles; Abbott
Recruiting - verified August 2012 - Conditions: Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: FOLFOX regimen; Drug: selumetinib
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Brain Metastases From Non-small Cell Lung Cancer
Interventions: Drug: Veliparib; Drug: Veliparib; Drug: Placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Condition: Osteoarthritis
Interventions: Biological: ABT-981; Biological: Placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified March 2013 - Conditions: Menorrhagia; Metrorrhagia
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified May 2013 - Conditions: Adult Alveolar Soft-part Sarcoma; Adult Angiosarcoma; Adult Epithelioid Sarcoma; Adult Extraskeletal Chondrosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Neurofibrosarcoma; Chondrosarcoma; Endometrial Stromal Sarcoma; Mast Cell Sarcoma; Metastatic Adult Malignant Fibrous Histiocytoma of Bone; Ovarian Carcinosarcoma; Ovarian Sarcoma; Recurrent Adult Malignant Fibrous Histiocytoma of Bone; Recurrent Adult Soft Tissue Sarcoma; Small Intestine Leiomyosarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: alisertib; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Fibrosing Colonopathy in Patients With Cystic Fibrosis
Interventions: Biological: CREON; Biological: ZENPEP; Biological: ULTRESA; Biological: PANCREAZE; Biological: other non-sponsor pancreatic enzyme replacement therapy; Other: No pancreatic enzyme replacement therapy
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); Aptalis Pharma; Cystic Fibrosis Foundation; Janssen Research & Development, LLC
Recruiting - verified January 2013 - Condition: Irritable Bowel Syndrome
Intervention:
Sponsors: Abbott; Abbott; CHILTERN International GmbH
Recruiting - verified May 2013 - Conditions: Cervical Cancer; Lymphedema; Sexuality and Reproductive Issues
Interventions: Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: cone biopsy; Procedure: genitourinary surgical procedure; Procedure: loop electrosurgical excision procedure; Procedure: quality-of-life assessment; Procedure: therapeutic laparoscopic surgery; Procedure: therapeutic lymphadenectomy
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Pneumonia; Cardiac Surgery; Multiperforated Catheter; Analgesia; Critical Care Medicine
Interventions: Device: L bupivacaine; Drug: placebo
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Baxter Healthcare Corporation; WYM France; Abbott
Recruiting - verified January 2013 - Condition: Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation
Intervention: Device: THERMOCOOL® SMARTTOUCH™ Catheter
Sponsors: Biosense Webster, Inc.; Biosense Webster, Inc.
Recruiting - verified February 2013 - Conditions: Fibrolamellar Carcinoma; Fibrolamellar Liver Cancer
Interventions: Drug: everolimus; Drug: letrozole plus leuprolide; Drug: combination of everolimus, letrozole and leuprolide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; The Fibrolamellar Cancer Foundation; Dana-Farber Cancer Institute/Brigham and Women¹s Cancer Center and Massachusetts General Hospital Cancer Center; Johns Hopkins University; University of California, San Francisco; Abbott; Novartis Pharmaceuticals
Recruiting - verified April 2013 - Condition: Myocardial Infraction (MI)
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified March 2013 - Conditions: Arthritis; Arthritis, Rheumatoid; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Autoimmune Diseases
Interventions: Procedure: Magnetic resonance imaging (MRI); Other: Conventional biochemical and clinical examinations
Sponsors: King Christian X´Hospital for Rheumatic Diseases; Professor of Rheumatology, MD, DMSci, Kim Horslev-Petersen; King Christian X´Hospital for Rheumatic Diseases; Slagelse Hospital; Glostrup University Hospital, Copenhagen; Abbott
Recruiting - verified November 2012 - Condition: Hospitalized Elderly
Interventions: Other: Ready to Drink Flavored Beverage; Other: Ready to drink flavored beverage w/ AN 777
Sponsors: Abbott Nutrition; Abbott Nutrition
Recruiting - verified June 2012 - Conditions: Mitral Regurgitation; Mitral Valve Regurgitation
Intervention: Device: MitraClip System
Sponsors: Evalve; Evalve; Abbott Vascular
Recruiting - verified March 2013 - Condition: Crohn Disease
Interventions: Drug: Adalimumab; Drug: 6 Mercaptopurine
Sponsors: Tel-Aviv Sourasky Medical Center; Tel-Aviv Sourasky Medical Center; Abbott
Not yet recruiting - verified June 2012 - Conditions: HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Tumors Metastatic to Brain
Interventions: Drug: lapatinib ditosylate; Radiation: whole-brain radiation therapy
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified March 2013 - Condition: Psoriasis
Intervention:
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; French Health Products Safety Agency; Société de Dermatologie Française; Janssen, LP; Pfizer; Abbott; Merck
Not yet recruiting - verified June 2012 - Condition: Rheumatoid Arthritis
Intervention: Biological: Adalimumab
Sponsors: Karolinska Institutet; Ronald van Vollenhoven, prof.; Abbott
Not yet recruiting - verified June 2012 - Condition: Schizophrenia
Interventions: Drug: ABT-126; Drug: ABT-126; Drug: ABT-126; Drug: Placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Condition: Psoriasis
Intervention: Other: 4 mm punch biopsies
Sponsors: University of Aarhus; University of Aarhus; Abbott; Aage Bangs Fond; Aase and Ejnar Danielsens Foundation; Direktør Jacob Madsens Og Hustru Olga Madsens Fond; Snedkermester Sophus Jacobsen og Hustru Astrid Jacobsens Fond
Recruiting - verified January 2013 - Condition: Moderate to Severe Plaque Psoriasis
Intervention: Biological: Adalimumab
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified March 2013 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: ABT-199; Drug: Bendamustine; Drug: Rituximab
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); Genentech
Recruiting - verified April 2013 - Condition: Type 1 Diabetes Mellitus
Intervention: Device: Heart rate informed SSM+HMM
Sponsors: University of Virginia; University of Virginia; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); DexCom, Inc.; Insulet Corporation; Abbott Diabetes Care
Recruiting - verified June 2012 - Condition: Driveline Heart-assisted Device Related Infection
Intervention:
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013 - Condition: Coronary Artery Disease
Intervention: Device: CADence System
Sponsors: AUM Cardiovascular, Inc.; AUM Cardiovascular, Inc.
Not yet recruiting - verified July 2012 - Condition: Psoriatic Arthritis
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); CATO Research Canada; JSS Medical Research Inc.
Recruiting - verified May 2013 - Conditions: Obesity; Diabetes
Intervention:
Sponsors: Universidad de Granada; Universidad de Granada; Spanish-Andalusian Ministry of Economy, Innovation and Science; Abbott; Scottish Government NuGO EU Project; University of Barcelona; ICTAN-CSIC - Madrid - Spain; Ludwig-Maximilians - University of Munich; University of Nottingham; University of Aberdeen; Agencia Andaluza del Conocimiento
Recruiting - verified July 2012 - Conditions: Plaque Psoriasis; Crohn's Disease
Interventions: Drug: Adalimumab; Device: Capsule endoscopy
Sponsors: Innovaderm Research Inc.; Innovaderm Research Inc.; Abbott
Recruiting - verified May 2013 - Condition: Ulcerative Colitis
Intervention: Biological: Adalimumab
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Condition: Alzheimer's Disease
Interventions: Drug: ABT-126; Drug: ABT-126; Drug: placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Condition: Breast Cancer
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Docetaxel; Drug: Paclitaxel
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified April 2013 - Condition: Non-Small -Cell Lung Cancer
Interventions: Drug: Veliparib; Drug: Carboplatin; Drug: paclitaxel; Drug: placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Condition: Alzheimer's Disease
Interventions: Drug: placebo; Drug: donepezil; Drug: ABT-126
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Conditions: Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Refractory Anemia With Excess Blasts; Secondary Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: lenalidomide; Drug: vorinostat
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013 - Condition: Colorectal Cancer
Interventions: Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2013 - Condition: Metastatic Breast Cancer
Interventions: Drug: Veliparib; Drug: Temozolomide; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Condition: Ulcerative Colitis
Intervention: Drug: Adalimumab
Sponsors: Clalit Health Services; Clalit Health Services
Recruiting - verified October 2012 - Condition: Arthritis; Behcet
Intervention: Drug: Adalimumab (Humira)
Sponsors: Rambam Health Care Campus; Rambam Health Care Campus; Abbott
Not yet recruiting - verified June 2012 - Condition: Coronary Artery Disease
Interventions: Device: platinum chromium everolimus-eluting stent; Device: cobalt chromium everolimus-eluting stent
Sponsors: University of Roma La Sapienza; University of Roma La Sapienza
Not yet recruiting - verified March 2013 - Condition: Metastatic Pancreatic Cancer
Intervention: Drug: Veliparib and 5-FU and Oxaliplatin and Leucovorin
Sponsors: Georgetown University; Georgetown University; Abbott
Recruiting - verified March 2013 - Conditions: Ankylosing Spondylitis; Psoriatic Arthritis
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2013 - Condition: Hidradenitis Suppurativa (HS)
Interventions: Biological: adalimumab; Biological: placebo; Biological: adalimumab
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified March 2013 - Condition: Hidradenitis Suppurativa (HS)
Interventions: Biological: adalimumab; Biological: placebo; Biological: adalimumab
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified March 2013 - Conditions: Arthritis; Rheumatoid
Intervention:
Sponsors: AbbVie; Abbott (China)
Recruiting - verified March 2013 - Conditions: Dyslipidemias; Cardiovascular Diseases; Hypertriglyceridemia
Intervention: Drug: fenofibrate
Sponsors: Abbott; Abbott; RUNDO International Pharmaceuticals Research & Development Co., Ltd
Recruiting - verified February 2013 - Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Non-Hodgkin Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma
Interventions: Drug: alisertib; Genetic: fluorescence in situ hybridization; Genetic: microarray analysis; Genetic: mutation analysis; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified March 2013 - Condition: Crohn's Disease
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Condition: Recurrent, Epithelial Ovarian Cancer
Intervention: Drug: Veliparib
Sponsors: Vejle Hospital; Vejle Hospital; Abbott
Recruiting - verified January 2013 - Condition: Advanced Solid Tumors
Interventions: Drug: ABT-700; Drug: ABT-700 plus Oxaliplatin and Capecitabine
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified March 2013 - Conditions: Gastrointestinal Hemorrhage; Clostridium Difficile Colitis
Interventions: Drug: Pantoprazole 40 mg IV daily and tube feed.; Other: Placebo and tube feed
Sponsors: University of Louisville; Mohamed Saad; Abbott Nutrition; University of Louisville
Not yet recruiting - verified January 2013 - Condition: Contrast Induced Nephropathy
Interventions: Device: RenalGuard Therapy; Drug: Standard Therapy
Sponsors: PLC Medical Systems, Inc.; PLC Medical Systems, Inc.
Recruiting - verified April 2013 - Conditions: Carotid Artery Disease; Stroke; Amaurosis Fugax; Transient Ischemic Attack (TIA)
Intervention: Device: RX Acculink Carotid Stent System (RX Acculink)
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified January 2013 - Condition: Peripheral Arterial Disease
Intervention: Device: stent
Sponsors: Flanders Medical Research Program; Flanders Medical Research Program
Recruiting - verified January 2013 - Conditions: Critical Illness; Enteral Feeding
Interventions: Other: VITAL AF; Other: Osmolite 1.2
Sponsors: Columbia University; Columbia University; Abbott Nutrition
Recruiting - verified July 2012 - Conditions: Peripheral Artery Disease; Peripheral Vascular Disease
Intervention: Device: Stenting using Absolute Pro® and Pro LL® Peripheral Stent Systems
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified March 2013 - Conditions: Breast Cancer; Cancer Survivor; Hot Flashes
Interventions: Drug: magnesium oxide; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2013 - Conditions: Coronary Artery Disease; Angina Pectoris
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013 - Conditions: Disorder of Transplanted Kidney; Proteinuria; Albuminuria
Interventions: Drug: Paricalcitol; Drug: Placebo
Sponsors: University Medical Centre Ljubljana; University Medical Centre Ljubljana; Abbott
Recruiting - verified September 2012 - Conditions: Cystic Fibrosis; Exocrine Pancreatic Insufficiency; Pancreatic Diseases; Digestive System Diseases
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified May 2013 - Conditions: Exocrine Pancreatic Insufficiency; Pancreatic Diseases; Digestive System Diseases
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified February 2013 - Conditions: Heavy Uterine Bleeding; Uterine Fibroids
Interventions: Drug: Placebo; Drug: Elagolix, elagolix sodium; Drug: Placebo; Drug: elagolix, elagolix sodium; Other: Elagolix Dose 1 plus estradiol/norethindrone acetate; Drug: Placebo; Drug: Elagolix, elagolix sodium; Drug: Elagolix, elagolix sodium; Drug: elagolix, elagolix sodium; Drug: Elagolix Dose 2 plus estradiol; Drug: Elagolix Dose 2 plus cyclical progesterone
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified March 2013 - Condition: Coronary Artery Disease
Interventions: Device: Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System; Device: Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified March 2013 - Conditions: Malnourished; Stomach Neoplasms; Gastrointestinal Stromal Tumors
Intervention: Dietary Supplement: Ensure powder
Sponsors: Seoul National University Hospital; Seoul National University Hospital; Abbott
Recruiting - verified December 2012 - Condition: Uncontrolled Hypertension
Intervention: Device: Renal denervation (Symplicity Catheter System)
Sponsors: Medtronic Vascular; Medtronic Vascular
Recruiting - verified May 2013 - Conditions: Lymphoma; Neurotoxicity; Therapy-related Toxicity
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: bortezomib; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2012 - Conditions: Cervical Cancer; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Sexuality and Reproductive Issues
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2012 - Condition: Arthritis, Juvenile Rheumatoid
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: methotrexate; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2012 - Conditions: Carotid Artery Disease; Stroke
Intervention: Procedure: Type of embolic protection method
Sponsors: Dallas VA Medical Center; American Heart Association
Recruiting - verified August 2011 - Conditions: Myocardial Infarction; Multivessel Coronary Artery Disease
Interventions: Procedure: FFR-guided revascularisation strategy; Procedure: randomised to guidelines group
Sponsors: Maasstad Hospital; Maasstad Hospital; Abbott Vascular; St. Jude Medical
Recruiting - verified December 2012 - Condition: Coronary Artery Disease
Interventions: Device: Biolimus-eluting stent; Device: Everolimus-eluting stent; Device: Zotarolimus-eluting stent
Sponsors: Yonsei University; Yonsei University; Gangwon Cardiovascular Health Research Institute
Recruiting - verified March 2013 - Condition: Type 2 Diabetes
Interventions: Drug: Paricalcitol; Other: placebo
Sponsors: Mario Negri Institute for Pharmacological Research; Mario Negri Institute for Pharmacological Research; Abbott
Recruiting - verified February 2013 - Conditions: Moderate to Severe Plaque Psoriasis; Antibodies; Monoclonals
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); Mag. Andreas Raffeiner GMBH
Recruiting - verified April 2013 - Condition: Psoriasis
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); CATO Research Canada; JSS Medical Research Inc.
Recruiting - verified May 2013 - Condition: Ankylosing Spondylitis
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); CATO Research Canada; JSS Medical Research Inc.
Recruiting - verified May 2013 - Condition: Prostate Cancer
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); CMX Research; JSS Medical Research Inc.
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Conditions: End-Stage Renal Disease; Secondary Hyperparathyroidism
Intervention: Drug: paricalcitol
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Condition: Brain Injury
Intervention: Drug: 1: Sevoflurane
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Ministry of Health, France
Recruiting - verified December 2012 - Conditions: Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Congestive Heart Failure
Interventions: Device: HM II® (HeartMate II® LVAD); Other: OMM (Optimal Medical Management)
Sponsors: University of Michigan; University of Michigan; National Heart, Lung, and Blood Institute (NHLBI); Thoratec Corporation
Not yet recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Intervention: Other: Observational study
Sponsors: Canadian Research & Education in Arthritis; Canadian Research & Education in Arthritis; Abbott
Recruiting - verified November 2011 - Conditions: Uveitis; Juvenile Arthritis
Interventions: Drug: Anti-tumor necrosis factor alpha monoclonal antibody; Drug: placebo
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Abbott
Recruiting - verified April 2013 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Other: R-CHOP regimen; Other: laboratory biomarker analysis; Radiation: fludeoxyglucose F 18; Radiation: selective external radiation therapy; Radiation: yttrium Y 90 ibritumomab tiuxetan
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2012 - Conditions: Head and Neck Cancer; Oropharyngeal Cancer; Human Papillomavirus; Squamous Cell Cancer
Intervention:
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine
Recruiting - verified July 2012 - Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo; Drug: eflornithine & sulindac placebo; Drug: Eflornithine placebo & sulindac; Drug: Eflornithine plus sulindac
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); Cancer Prevention Pharmaceuticals, Inc.
Recruiting - verified May 2013 - Condition: Coronary Artery Disease
Intervention:
Sponsors: CardioVascular Research Foundation, Korea; Seung-Jung Park; CardioVascular Research Foundation, Korea; Abbott
Recruiting - verified August 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Condition: Primary Biliary Cirrhosis
Intervention: Drug: Truvada and Kaletra
Sponsors: University of Alberta; University of Alberta; Abbott; Gilead Sciences; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified June 2012 - Condition: Crohn's Disease
Intervention: Drug: Adalimumab and Infliximab
Sponsors: University Hospital, Ghent; University Hospital, Ghent; Abbott
Recruiting - verified February 2013 - Conditions: Fallopian Tube; Primary Peritoneal Cancer; Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian,
Intervention: Drug: ABT-767
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Condition: Psoriasis
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); pH Associates
Recruiting - verified May 2013 - Condition: Ankylosing Spondylitis
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Condition: HIV-1 Infection
Interventions: Procedure: cervical cryotherapy; Procedure: Loop Electrosurgical Excision Procedure (LEEP)
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2012 - Condition: Heart Diseases
Interventions: Dietary Supplement: Ensure, Abbott Nutrition; Other: standard hospital diet
Sponsors: Meshalkin Research Institute of Pathology of Circulation; Meshalkin Research Institute of Pathology of Circulation
Recruiting - verified December 2012 - Conditions: Oropharyngeal Cancer; Human Papillomavirus
Intervention:
Sponsors: Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; Mount Sinai School of Medicine; Oregon Health and Science University; Dana-Farber Cancer Institute; Johns Hopkins Hospital (JHH)
Recruiting - verified May 2013 - Conditions: Chlamydia Infection; Gonococcal Infection; Sexually Transmitted Diseases
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; Abbott Molecular
Recruiting - verified June 2012 - Condition: Mitral Regurgitation
Intervention: Device: MitraClip Implant
Sponsors: Evalve; Evalve; Abbott
Recruiting - verified September 2012 - Condition: Atherosclerosis of Native Arteries of the Extremities, Unspecified
Intervention: Device: Stent implantation
Sponsors: Boston Scientific Corporation; Boston Scientific Corporation
Recruiting - verified April 2013 - Condition: Contrast Media Induced Nephropathy (CIN)
Interventions: Other: application of intravenous volume; Other: oral fluid application
Sponsors: Medical University of Graz; Medical University of Graz; Abbott Diagnostics Division
Recruiting - verified September 2012 - Conditions: Acute Decompensated Heart Failure; Acute Kidney Injury
Intervention:
Sponsors: Alere San Diego; Alere San Diego; Abbott Diagnostics Division; Alere, Inc.
Recruiting - verified June 2012 - Condition: Oral Mucositis
Interventions: Device: MuGard; Device: Control Rinse
Sponsors: Access Pharmaceuticals, Inc.; Access Pharmaceuticals, Inc.
Recruiting - verified June 2012 - Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerConditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: docetaxel; Drug: cyclophosphamide; Biological: trastuzumab; Drug: paclitaxel; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b; Other: pharmacological study; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013 - Conditions: Coronary Artery Disease; Aortic Aneurysm; Pulmonary Embolism
Intervention:
Sponsors: William Beaumont Hospitals; Gilbert L. Raff, MD; Siemens Healthcare Diagnostics Inc
Recruiting - verified September 2012 - Conditions: Acute Pancreatitis; Enteral Nutrition
Interventions: Dietary Supplement: T-Diet plus Atémpero; Dietary Supplement: AlitraQ (Abbott)
Sponsors: Vegenat, S.A.; Vegenat, S.A.
Recruiting - verified February 2011 - Conditions: Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: bicalutamide; Other: clinical observation
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Procedure: palliative surgery; Procedure: therapeutic conventional surgery; Radiation: palliative radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2012 - Condition: Crohn's Disease
Interventions: Biological: adalimumab; Drug: prednisone; Drug: azathioprine
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Conditions: Critical Illness; Hyperglycemia; Mechanical Ventilation; Enteral Nutrition; Metabolic Stress
Interventions: Dietary Supplement: T-Diet plus Diabet IR; Dietary Supplement: ISOSOURCE PROTEIN FIBRE; Dietary Supplement: GLUCERNA SELECT
Sponsors: Vegenat, S.A.; Vegenat, S.A.
Recruiting - verified November 2010 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: bortezomib; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2012 - Conditions: Chronic Coronary Occlusion; Unprotected Left Main Coronary Artery Disease; Stent Thrombosis; Vascular Disease; Myocardial Ischemia; Coronary Artery Stenosis; Coronary Disease; Coronary Artery Disease; Coronary Restenosis
Interventions: Device: Percutaneous Coronary Intervention; Procedure: CABG
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified April 2013 - Condition: Rheumatoid Arthritis
Intervention: Device: Ultrasonography
Sponsors: Diakonhjemmet Hospital; Espen A. Haavardsholm; The Research Council of Norway; Smerud Medical Research International AS; Oslo University Hospital, Section for GCP; Innovest; Abbott; UCB NORDIC A/S; Pfizer; MSD Norway AS; Roche Pharma AG; The Norwegian Rheumatism Association
Recruiting - verified May 2013 - Conditions: Diarrhea; Gastrointestinal Complications; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sulfasalazine; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2013 - Conditions: Adenocarcinoma of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Stage IB Esophageal Cancer; Stage IIA Esophageal Cancer; Stage IIB Esophageal Cancer; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer
Interventions: Radiation: radiation therapy; Drug: paclitaxel; Drug: carboplatin; Biological: trastuzumab; Procedure: therapeutic conventional surgery; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified March 2013 - Condition: HIV-1
Interventions: Drug: Efavirenz or Nevirapine; Drug: Ritonavir-boosted lopinavir
Sponsors: University of Aarhus; University of Aarhus; Aarhus University Hospital; Bandim Health Project; Ministry of Health, Guinea-Bissau; Abbott
Recruiting - verified September 2012 - Conditions: Light Chain Deposition Disease; Smoldering Multiple Myeloma
Interventions: Other: clinical observation; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Primary Peritoneal Cavity Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Primary Peritoneal Cavity Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Epithelial Cancer; Stage IIC Primary Peritoneal Cavity Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Primary Peritoneal Cavity Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Primary Peritoneal Cavity Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Primary Peritoneal Cavity Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: carboplatin; Biological: bevacizumab; Procedure: neoadjuvant therapy; Procedure: adjuvant therapy; Procedure: therapeutic conventional surgery; Procedure: computed tomography
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified March 2013 - Conditions: Spondyloarthritis; Intestinal Inflammation
Intervention: Drug: Adalimumab
Sponsors: Regionshospitalet Silkeborg; Regionshospitalet Silkeborg; Abbott; European Capsule Endoscopy Group; The Central Denmark Region
Recruiting - verified July 2012 - Condition: Moderate to Severe Psoriasis
Intervention:
Sponsors: AbbVie; Abbott (Peru)
Recruiting - verified May 2013 - Conditions: Head and Neck Cancer; Mucositis; Oral Complications of Radiation Therapy; Pain
Interventions: Drug: doxepin hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2013 - Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2013 - Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size; Ciliary Body and Choroid Melanoma, Small Size; Iris Melanoma; Metastatic Intraocular Melanoma; Recurrent Intraocular Melanoma
Interventions: Drug: selumetinib; Drug: temozolomide; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Arthritis, Rheumatoid
Interventions: Biological: adalimumab; Drug: Methotrexate
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); Mount Sinai Hospital, Canada
Recruiting - verified March 2013 - Condition: Epithelial Ovarian Cancer
Interventions: Procedure: CA125 assay on Abbott Architect i1000SR platform; Procedure: HE4 assay on Architect i1000SR platform; Procedure: Transvaginal Ultrasound
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; The Marsha Rivkin Center for Ovarian Cancer Research; Canary Foundation; Swedish Medical Center; Beckman Research Institute; Cedars-Sinai Medical Center; Stanford University; Fox Chase Cancer Center
Recruiting - verified March 2013 - Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: prednisone; Drug: adalimumab placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo; Drug: prednisone
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2012 - Condition: Kidney Cancer
Interventions: Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2012 - Condition: Chronic Kidney Disease
Intervention: Drug: Zemplar
Sponsors: Danderyd Hospital; Danderyd Hospital; Abbott
Recruiting - verified April 2013 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: pemetrexed disodium
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2012 - Conditions: Multiple Trauma; Head Trauma
Interventions: Dietary Supplement: Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.; Dietary Supplement: oxepa; Dietary Supplement: Control group
Sponsors: Rabin Medical Center; Rabin Medical Center; Israeli Ministry of Security
Recruiting - verified February 2013 - Condition: Gastric Cancer
Intervention: Drug: Veliparib
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Condition: Advanced Solid Tumors
Interventions: Drug: ABT-348; Drug: ABT-348 and carboplatin; Drug: ABT-348 and docetaxel; Drug: ABT-348; Drug: ABT-348
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Conditions: Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; B-cell Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Myelodysplasia
Interventions: Drug: ABT-348; Drug: ABT-348; Drug: ABT-348 and azacitidine; Drug: ABT-348
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Conditions: Crohn's Disease; Rheumatoid Arthritis
Intervention:
Sponsors: University of California, San Diego; University of California, San Diego; The Organization of Teratology Information Specialists; Abbott
Recruiting - verified February 2013 - Condition: Respiratory Syncytial Virus Infections
Intervention: Drug: palivizumab (Synagis)
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Conditions: Rheumatoid Arthritis; Osteoporosis
Intervention:
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); Masaryk University
Recruiting - verified March 2013 - Condition: Human Immunodeficiency Virus
Intervention: Drug: Lopinavir/Ritonavir (Kaletra)
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott); Veeda Clinical Research, Belgium
Recruiting - verified April 2013 - Condition: Crohn´s Disease
Intervention: Biological: adalimumab (Humira)
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Condition: Moderate to Severe Plaque Psoriasis
Intervention: Biological: adalimumab (Humira)
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Condition: Rheumatoid Arthritis
Intervention: Biological: adalimumab (Humira)
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Condition: Human Immunodeficiency Virus
Interventions: Drug: lopinavir/ritonavir; Drug: Raltegravir; Drug: Maraviroc; Drug: Rilpivirine; Drug: Etravirine
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified February 2013 - Condition: Crohn's Disease
Intervention:
Sponsors: Haukeland University Hospital; Haukeland University Hospital; University of Bergen; Abbott
Recruiting - verified November 2012 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: celecoxib; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2013 - Conditions: Myocardial Ischemia; Coronary Artery Stenosis; Coronary Disease; Coronary Artery Disease; Coronary Restenosis; Cardiovascular Disease
Intervention: Device: ABSORB BVS
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified February 2013 - Condition: Lung Cancer
Interventions: Biological: Seneca Valley virus-001; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2013 - Conditions: Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Recurrent Adult Primary Liver Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013 - Condition: Chronic Kidney Disease Stage 3 and 4
Interventions: Drug: Zemplar (paricalcitol) Capsules; Drug: Placebo capsules
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Conditions: Recurrent Uterine Sarcoma; Stage IIIA Uterine Sarcoma; Stage IIIB Uterine Sarcoma; Stage IIIC Uterine Sarcoma; Stage IVA Uterine Sarcoma; Stage IVB Uterine Sarcoma; Uterine Leiomyosarcoma
Interventions: Other: placebo; Biological: bevacizumab; Drug: gemcitabine hydrochloride; Drug: docetaxel; Biological: filgrastim; Biological: pegfilgrastim
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified January 2013 - Conditions: Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Endometrial Papillary Serous Carcinoma; Localized Unresectable Adult Primary Liver Cancer; Metastatic Gastrointestinal Carcinoid Tumor; Ovarian Carcinosarcoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Papillary Serous Carcinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Alpha Cell Carcinoma; Pancreatic Beta Islet Cell Adenoma; Pancreatic Beta Islet Cell Carcinoma; Pancreatic Delta Cell Adenoma; Pancreatic Delta Cell Carcinoma; Pancreatic G-cell Adenoma; Pancreatic G-cell Carcinoma; Pancreatic Polypeptide Tumor; Pulmonary Carcinoid Tumor; Recurrent Adult Primary Liver Cancer; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Cancer; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Regional Gastrointestinal Carcinoid Tumor; Stage IIIA Endometrial Carcinoma; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Primary Peritoneal Cavity Cancer; Stage IIIB Endometrial Carcinoma; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Primary Peritoneal Cavity Cancer; Stage IIIC Endometrial Carcinoma; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Primary Peritoneal Cavity Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Primary Peritoneal Cavity Cancer; Stage IVA Endometrial Carcinoma; Stage IVB Endometrial Carcinoma; Uterine Carcinosarcoma
Interventions: Drug: temsirolimus; Biological: bevacizumab
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified November 2012 - Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: carvedilol phosphate extended-release capsule; Drug: lisinopril; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified January 2013 - Condition: Coronary Artery Disease
Interventions: Device: everolimus-eluting stent; Procedure: coronary artery bypass graft surgery
Sponsors: CardioVascular Research Foundation, Korea; Seung-Jung Park; Abbott Vascular; CardioVascular Research Foundation, Korea
Recruiting - verified August 2012 - Condition: Myocardial Ischemia
Intervention: Genetic: VM202
Sponsors: ViroMed Co., Ltd.; ViroMed Co., Ltd.; VM Biopharma
Not yet recruiting - verified November 2012 - Condition: Cerebral Aneurysms
Intervention:
Sponsors: Mayo Clinic; David F. Kallmes; Abbott; Albany Medical College; Asan Medical Center; Baylor University; Capital Health, Canada; The Cleveland Clinic; Dalhousie University; Fudan University; JFK Medical Center, Florida; Mayo Clinic; MUSC; Providence Health & Services; Stony Brook University; Thomas Jefferson University; Royal University Hospital Foundation; University of California, Los Angeles; University of Florida; University of Maryland; University of Oklahoma; University of Southern California; Washington University School of Medicine
Recruiting - verified January 2013 - Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2012 - Condition: Lung Cancer
Interventions: Biological: panitumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2012 - Condition: Melanoma (Skin)
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: everolimus; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2013 - Condition: Atherosclerosis
Intervention:
Sponsors: Piedmont Healthcare; Piedmont Healthcare; Abbott
Recruiting - verified December 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer; Psychosocial Effects of Cancer and Its Treatment
Interventions: Other: communication intervention; Other: educational intervention; Other: internet-based intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: management of therapy complications; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2012 - Conditions: Adenocarcinoma of the Lung; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Biological: cixutumumab; Drug: paclitaxel; Drug: carboplatin; Biological: bevacizumab
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified March 2013 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2013 - Conditions: Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Prostate Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: cisplatin; Other: placebo; Biological: bevacizumab; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2012 - Condition: HIV Infections
Interventions: Drug: Isentress®; Drug: Celsentri®
Sponsors: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer; Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer; Merck; Abbott
Recruiting - verified July 2009 - Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: dasatinib; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2013 - Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma; Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); Novartis
Recruiting - verified January 2013 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: dasatinib; Drug: temozolomide; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2013 - Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; The Kirby Institute for Infection and Immunity in Society; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified May 2013 - Condition: Juvenile Idiopathic Arthritis
Interventions: Biological: adalimumab; Drug: Methotrexate
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013 - Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2012 - Conditions: Cognitive/Functional Effects; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer; Weight Changes
Interventions: Behavioral: behavioral dietary intervention; Behavioral: compliance monitoring; Behavioral: exercise intervention; Behavioral: telephone-based intervention; Other: counseling intervention; Other: educational intervention; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2012 - Conditions: Coronary Artery Disease; Carotid Artery Diseases; Atherosclerosis
Interventions: Drug: Atorvastatin; Drug: Niacin; Drug: Colesevelam; Drug: Placebo Niacin; Drug: Placebo Colesevelam
Sponsors: University of Washington; University of Washington; National Heart, Lung, and Blood Institute (NHLBI); Pfizer; Abbott; Daiichi Sankyo Inc.; Upsher-Smith Laboratories
Recruiting - verified December 2012 - Conditions: Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified December 2012 - Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified February 2013 - Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: melphalan; Drug: prednisone; Drug: thalidomide; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Tongue Cancer; Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Drug: docetaxel; Drug: cisplatin; Drug: carboplatin; Drug: fluorouracil; Biological: bevacizumab
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified March 2013 - Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified September 2012 - Conditions: Brenner Tumor; Fallopian Tube Cancer; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Primary Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial Cancer
Interventions: Drug: paclitaxel; Drug: docetaxel; Drug: carboplatin; Biological: bevacizumab; Drug: gemcitabine hydrochloride; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified March 2013 - Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: gemtuzumab ozogamicin; Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2013 - Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013 - Condition: Small Intestine Cancer
Interventions: Drug: capecitabine; Drug: irinotecan hydrochloride; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified November 2012 - Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified February 2013 - Condition: Coronary Artery Disease
Interventions: Drug: AndroGel 5 Grams; Drug: Placebo
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine; Abbott
Recruiting - verified July 2012 - Conditions: HIV Infections; Hepatitis B Virus
Intervention:
Sponsors: INC Research; INC Research; Abbott; Apotex Inc.; Aurobindo; Boehringer Ingelheim Pharmaceuticals; Bristol-Myers Squibb; Cipla Ltd.; Gilead Sciences; HEC Pharm; Hetero USA; IPCA Laboratories Ltd.; Janssen R&D Ireland; Merck; Mylan Laboratories; Novartis; Pfizer; Prinston; Ranbaxy Inc.; Roche Pharma AG; Sciegen Pharmaceuticals; Strides Arcolab Ltd.; Teva Pharmaceuticals USA; ViiV Healthcare (represented by GlaxoSmithKline)
Recruiting - verified April 2013 - Conditions: Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer
Interventions: Biological: ziv-aflibercept; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013 - Conditions: Migraine Headaches; Patent Foramen Ovale
Interventions: Other: Sham Procedure; Device: AMPLATZER PFO Occluder
Sponsors: AGA Medical Corporation; AGA Medical Corporation
Recruiting - verified February 2013 - Conditions: Stage IB Non-small Cell Lung Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: vinorelbine tartrate; Drug: cisplatin; Drug: docetaxel; Drug: pemetrexed disodium; Biological: bevacizumab; Other: questionnaire administration; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); Southwestern Oncology Group (SWOG); North Central Cancer Treatment Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group
Recruiting - verified March 2013 - Condition: Anal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2012 - Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2012 - Conditions: Mitral Valve Insufficiency; Mitral Valve Regurgitation; Mitral Valve Incompetence; Mitral Regurgitation; Mitral Insufficiency
Interventions: Device: Percutaneous mitral valve repair using MitraClip implant; Procedure: Mitral valve repair or replacement surgery
Sponsors: Evalve; Evalve
Recruiting - verified October 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: paclitaxel poliglumex; Other: clinical observation
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI); CTI
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal accelerated partial breast irradiation; Radiation: brachytherapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified October 2012 - Condition: Leukemia
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: lenalidomide; Drug: pentostatin
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2012
 |
Abbott Laboratories - Database of Clinical Trials by Pharmaceutical Companies |
Clinical Trial Locations 